CN100341526C - 一种含有抱茎苦荬菜提取物的制剂及其制备方法 - Google Patents
一种含有抱茎苦荬菜提取物的制剂及其制备方法 Download PDFInfo
- Publication number
- CN100341526C CN100341526C CNB2004100781680A CN200410078168A CN100341526C CN 100341526 C CN100341526 C CN 100341526C CN B2004100781680 A CNB2004100781680 A CN B2004100781680A CN 200410078168 A CN200410078168 A CN 200410078168A CN 100341526 C CN100341526 C CN 100341526C
- Authority
- CN
- China
- Prior art keywords
- extract
- herba ixeritis
- ixeritis sonchifoliae
- preparation
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 241001301715 Crepidiastrum sonchifolium Species 0.000 title abstract description 24
- 238000000034 method Methods 0.000 title description 14
- 239000003814 drug Substances 0.000 claims abstract description 72
- 238000002347 injection Methods 0.000 claims abstract description 38
- 239000007924 injection Substances 0.000 claims abstract description 38
- 229930003944 flavone Natural products 0.000 claims abstract description 11
- 235000011949 flavones Nutrition 0.000 claims abstract description 11
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 10
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 10
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 10
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 5
- 229960005305 adenosine Drugs 0.000 claims abstract description 5
- VSUOKLTVXQRUSG-UHFFFAOYSA-N Lgr Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 VSUOKLTVXQRUSG-UHFFFAOYSA-N 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 229940079593 drug Drugs 0.000 claims description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 23
- 239000003960 organic solvent Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- -1 electuary Substances 0.000 claims description 14
- 238000004440 column chromatography Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 239000008394 flocculating agent Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000004952 Polyamide Substances 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 229920002647 polyamide Polymers 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- HYGKYXGLJBDJOX-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one;2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1.C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 HYGKYXGLJBDJOX-UHFFFAOYSA-N 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 description 65
- 241000700159 Rattus Species 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 30
- 230000000302 ischemic effect Effects 0.000 description 25
- 210000004556 brain Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000013641 positive control Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 14
- 201000006474 Brain Ischemia Diseases 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 13
- 230000003727 cerebral blood flow Effects 0.000 description 13
- 239000008354 sodium chloride injection Substances 0.000 description 13
- 206010008120 Cerebral ischaemia Diseases 0.000 description 12
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 206010008118 cerebral infarction Diseases 0.000 description 11
- 229960003699 evans blue Drugs 0.000 description 11
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 206010053567 Coagulopathies Diseases 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000035602 clotting Effects 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 7
- 210000001168 carotid artery common Anatomy 0.000 description 7
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000001705 Mouth breathing Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 235000001727 glucose Nutrition 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 5
- 208000029039 cyanide poisoning Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241001529246 Platymiscium Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000005622 photoelectricity Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241001412304 Ixeris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009811 bilateral tubal ligation Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 给药剂量(mg/kg) | 给药前 | 给药后 | ||||
1min | 5min | 30min | 60min | 120min | |||
生理盐水对照组注射用抱茎苦荬菜提取物注射用抱茎苦荬菜提取物注射用抱茎苦荬菜提取物碟脉灵注射液 | 1.63.26.40.67 | 50.21±7.6848.86±9.2451.79±8.3749.71±7.8149.60±9.71 | 49.36±7.7875.12±8.58##**78.22±7.24##**81.74±9.47##**77.47±7.32##** | 48.24±8.1678.38±6.08##**80.47±8.01##**83.19±7.21##**79.55±8.11##** | 51.12±7.4164.87±7.40#*68.51±9.20#*73.30±8.88##**68.47±9.23#* | 48.10±8.1456.68±7.3357.25±8.2462.58±9.23#*56.41±7.41 | 49.87±9.8151.37±9.9453.22±7.2556.77±9.4854.36±8.74 |
组别 | 给药剂量(mg/kg) | 给药前 | 给药后 | ||||
1min | 5min | 30min | 60min | 120min | |||
生理盐水对照组注射用抱茎苦荬菜提取物注射用抱茎苦荬菜提取物注射用抱茎苦荬菜提取物碟脉灵注射液 | 1.63.26.40.67 | 0.058±0.0100.055±0.0110.057±0.0120.055±0.0070.056±0.013 | 0.059±0.0090.045±0.012##**0.044±0.010##**0.042±0.013##**0.044±0.011##** | 0.059±0.0080.043±0.012##**0.042±0.013##**0.0041±0.011##**0.044±0.008##** | 0.058±0.0110.051±0.0090.047±0.010#*0.045±0.014##**0.048±0.013#* | 0.057±0.0100.052±0.0120.050±0.0070.049±0.0180.051±0.008 | 0.058±0.0090.055±0.0090.056±0.0080.051±0.0140.053±0.009 |
组别 | 给药剂量(mg/kg) | 给药途径 | 脑含水量% | 脑指数% |
对照组模型组抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物碟脉灵注射液 | 5.410.821.610.82.25 | ivivivivivigiv | 75.6±2.584.8±2.1##80.9±3.8*79.6±3.4**77.8±2.2**80.4±2.9*78.6±2.7** | 0.65±0.030.74±0.04##0.70±0.03*0.68±0.03*0.66±0.02**0.71±0.02*0.68±0.03* |
组别 | 给药剂量(mg/kg) | 给药途径 | MDA(mmol/g组织湿重) |
对照组模型组抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物碟脉灵注射液 | 5.410.821.610.82.25 | ivivivivivigiv | 401.4±36.7502.7±41.8##443.7±27.9**438.5±26.9**422.0±31.7**441.8±28.6**437.7±33.4** |
组别 | 给药剂量(mg/kg) | 给药途径 | 伊文思蓝(μg/g) |
对照组模型组抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物 | 5.410.821.6 | iviviviviv | 4.97±0.178.64±0.25##6.89±0.33**5.98±0.47**4.96±0.38** |
抱茎苦荬菜提取物碟脉灵注射液 | 10.82.25 | igiv | 6.68±0.56**6.31±0.62** |
组别 | 剂量(mg/kg) | 存活时间(min) |
对照组碟脉灵注射液抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物 | 3.257.815.631.2 | 5.21±1.317.11±1.48**6.42±1.14*6.50±1.33*7.52±1.45** |
组别 | 剂量(mg/kg) | 张口呼吸持续时间(秒) |
对照组碟脉灵注射液抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物 | 3.257.815.631.2 | 15.2±6.120.6±4.9*18.1±3.820.1±4.2*22.0±4.0** |
组别 | 剂量(mg/kg) | 存活时间(秒) |
对照组碟脉灵注射液抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物 | 3.257.815.631.2 | 36.1±11.146.2±9.5*43.0±10.346.4±10.1*52.3±11.2** |
组别 | 剂量(mg/kg) | 全血粘度 | 血浆粘度 | ||
高切 | 中切 | 低切 | |||
对照组模型组碟脉灵注射液抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物 | 2.255.410.821.6 | 3.916±1.0545.495±1.147△△4.483±0.949*4.816±0.8564.059±1.130*3.836±1.015** | 5.945±1.1928.155±1.189△△6.715±1.081*7.219±1.3676.329±1.453**6.141±1.089** | 13.031±1.98615.949±2.325△△12.850±1.860**13.372±1.843*13.024±2.130**12.790±1.190** | 1.679±0.3102.114±0.388△1.600±0.298**1.872±0.3341.655±0.405*1.576±0.292** |
组别 | 剂量(mg/kg) | 血小板聚集率(%) | |||
1min | 3min | 5min | MA | ||
对照组碟脉灵注射液抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物 | 1.172856112 | 4361±8253436±662*3834±7043338±568**3210±664** | 6281±8544659±7.10**5649±7924988±666**4408±798** | 5695±7844004±754**4965±6.77*4214±606**3909±660** | 6603±7885059±664**6321±8.425746±5.47*5043±662** |
组别 | 剂量(mg/kg) | 血栓长度(cm) | 湿重(mg) | 干重(mg) |
对照组碟脉灵注射液抱茎苦荬菜提取物抱茎苦荬菜提 | 1.172.85.6 | 4.49±1.052.88±1.30**3.99±0.773.12±1.47* | 236.1±55.6137.2±69.0**178.3±44.5*170.1±68.9* | 66.9±15.839.4±17.5**52.9±17.249.3±18.9* |
取物抱茎苦荬菜提取物 | 11.2 | 2.43±1.19** | 122.5±60.1** | 33.4±15.4** |
组别 | 剂量(mg/kg) | 凝血时间(min) | 出血时间(min) |
对照组碟脉灵注射液抱茎苦荬菜提取物抱茎苦荬菜提取物抱茎苦荬菜提取物 | 3.257.815.631.2 | 2.20±0.352.60±0.39*2.45±0.442.75±0.68*2.80±0.67* | 7.35±0.788.45±1.32*7.70±1.168.35±0.94*8.95±1.34* |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100781680A CN100341526C (zh) | 2004-09-20 | 2004-09-20 | 一种含有抱茎苦荬菜提取物的制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100781680A CN100341526C (zh) | 2004-09-20 | 2004-09-20 | 一种含有抱茎苦荬菜提取物的制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1616036A CN1616036A (zh) | 2005-05-18 |
CN100341526C true CN100341526C (zh) | 2007-10-10 |
Family
ID=34765467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100781680A Expired - Fee Related CN100341526C (zh) | 2004-09-20 | 2004-09-20 | 一种含有抱茎苦荬菜提取物的制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100341526C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104277083B (zh) * | 2013-07-04 | 2019-04-23 | 河北以岭医药研究院有限公司 | 一种木犀草素-7-o-β-D-葡萄糖醛酸苷制备方法及用途 |
CN105175464B (zh) * | 2015-06-17 | 2018-03-20 | 广东省农业科学院蚕业与农产品加工研究所 | 从龙眼肉中分离木犀草素5‑O‑β‑葡萄糖苷的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1377689A (zh) * | 2002-04-23 | 2002-11-06 | 张瑞香 | 一种治疗心脑血管和眼底病的中药针剂及其制备方法 |
-
2004
- 2004-09-20 CN CNB2004100781680A patent/CN100341526C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1377689A (zh) * | 2002-04-23 | 2002-11-06 | 张瑞香 | 一种治疗心脑血管和眼底病的中药针剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1616036A (zh) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101040915A (zh) | 一种双黄连注射液的制备方法及其成分检测方法 | |
CN1565583A (zh) | 治疗糖尿病及其并发症的中药组合物 | |
CN1557842A (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
CN1814170A (zh) | 一种治疗心血管疾病的药物滴丸及其制备方法 | |
CN100341526C (zh) | 一种含有抱茎苦荬菜提取物的制剂及其制备方法 | |
CN1712056A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN1436549A (zh) | 一种中药复方三七滴丸及其制备方法 | |
CN106309671A (zh) | 甘肃陇南大红袍花椒提取物组分及其制备方法与检测方法 | |
CN1947736A (zh) | 一种灯盏细辛注射制剂的制备方法及其应用 | |
CN109602759A (zh) | 罗汉松实多糖的用途 | |
CN1206236C (zh) | 刺五加总皂苷提取物及其药物组合物 | |
CN1060384C (zh) | 一种抗衰老药物口服液及其制备方法 | |
CN1857385A (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN1686462A (zh) | 一种复方血塞通注射制剂及其制备方法 | |
CN1202832C (zh) | 一种高活性银杏叶提取物制剂和用途 | |
CN1772089A (zh) | 一种含有白花蛇舌草冻干粉针剂及其制备方法 | |
CN1301099C (zh) | 地龙滴丸及其制备方法 | |
CN1682970A (zh) | 一种苦碟子注射制剂的制备方法 | |
CN1634413A (zh) | 一种勒马回注射制剂及其制备方法 | |
CN100333771C (zh) | 一种参芪降糖滴丸及其制备和检测方法 | |
CN1522747A (zh) | 一种治疗冠心病或冠心病合并心功能不全的药物及其制备方法 | |
CN1853701A (zh) | 一种洋参生脉药物的有效部位及其制备方法 | |
CN101966251B (zh) | 一种用于预防及治疗支气管哮喘的药物组合物及其制备与应用 | |
CN1943584A (zh) | 一种治疗心脑血管疾病的药物组合物及其制备方法 | |
CN1899369A (zh) | 一种救心注射制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HARBIN LONGSHENG BEIYAO BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: HONG CHUNLI Effective date: 20110324 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110000 NO. 13-2, NO. BEISIZHONG, BAOWEI STREET, TIEXI DISTRICT, SHENYANG CITY, LIAONING PROVINCE TO: 150070 ROOM 152, MANAGEMENT BUILDING, NO. 368, YANGTSE RIVER ROAD, NANGANG CONCENTRATED ZONE, HARBIN ECONOMIC DEVELOPMENT ZONE, HEILONGJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110324 Address after: 150070 room 368, management building, 152 Changjiang Road, Nangang concentration area, Harbin, Heilongjiang Patentee after: HARBIN LONGSHENG BEIYAO BIOENGINEERING CO., LTD. Address before: 110000, No. 13-2, No.4, defending street, Tiexi District, Liaoning, Shenyang Patentee before: Hong Chunli |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071010 Termination date: 20110920 |